Overview
Aprepitant for Postoperative Nausea and Vomiting in Laparoscopic Hysterectomy
Status:
Completed
Completed
Trial end date:
2010-09-01
2010-09-01
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
- Gynecological surgery is associated with a high incidence of postoperative nausea and vomiting. - NK1 receptor antagonists such as aprepitant appear to be highly effective for treating acute and delayed emesis, and yet understanding of the efficacy of different doses of aprepitant is limited. - We performed a prospective, randomized, double-blinded placebo-controlled study of 123 female adults scheduled for laparoscopic hysterectomy who received 80 mg aprepitant, 125 mg aprepitant, or a placebo.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Gachon University Gil Medical CenterCollaborators:
Asan Medical Center
University of California, San FranciscoTreatments:
Aprepitant
Fosaprepitant
Criteria
Inclusion Criteria:- female laparoscopic hysterectomy isoflurane anesthesia postoperative opioid use
Exclusion Criteria:
- liver disease neurologic disease active pulmonary disease cardiac arrhythmia allergies
to any perioperative medications